Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
Brent N. Rexer(Vanderbilt University Medical Center), Carlos L. Arteaga(The University of Texas Southwestern Medical Center)
Cited by 77
Related Papers
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer
|Breast Cancer Research|2011|463
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab
|Cancer Discovery|2021|241
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
|JNCI Journal of the National Cancer Institute|2019|168
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
|Nature Genetics|2015|166
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated Tumor
|JAMA Oncology|2020|106